Bridging perspectives from prevention, diagnosis, management to economic aspects: the voice of Belgian cardiologists

Figures & data

Figure 1. Risk-based LDL-C goal attainment in patients categorised by lipid-lowering therapy (LLT). Patients (n = 410) on stabilised LLT therapy and evaluable for goal attainment. c: Ezetimabe combination: patients who were treated with ezetimibe plus statin of moderate, high or unknown intensity (from reference [6]).

Figure 2. Box plot showing subcategories of expenditure (€) (median; 25th–75th percentile; °outlier; *extreme value). Costs of SAVR are significantly higher than those of TAVI, for each of the subcategories except operational costs. Furthermore, non-medical staff is shown to be the largest item of expenditure for both groups, followed by operational costs and medical staff (from reference [23]).

Figure 3. Transthoracic echocardiography in a patient with mechanical prosthetic valve mitral valve replacement for systemic lupus erythematosus-induced Libman-Sacks endocarditis. (A) turbulent eccentric diastolic mitral inflow; (B) mean 9-mmHg pressure gradient; C-F: posterior leaflet stuck in closed position and a prosthetic mitral thrombus (arrow). (C and D) trans-esophageal echocardiography; € cinefluoroscopy; (G) cardiac computed tomography (from reference [26]).

van de Borne P, Peeters A, Janssens L, et al. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiol. 2022;79(1):20–29. doi: 10.1080/00015385.2022.2030568.

 Google Scholar

De Paepe J, Lamberigts M, Meuris B, et al. Transcatheter aortic valve implantation versus sutureless aortic valve replacement: a single-centre cost analysis. Acta Cardiol. 2023;79(1):32–42. doi: 10.1080/00015385.2023.2268441.

 Google Scholar

Truchart J, Plein D, Balthazar T, et al. Mechanical valve obstructive thrombosis in an asymptomatic patient: a gap in current recommendations. Acta Cardiol. 2023;79(1):77–78. doi: 10.1080/00015385.2023.2217386.

 Google Scholar